Association of plasma and cortical amyloid beta is modulated by APOE ε4 status
dc.contributor.author | Swaminathan, Shanker | |
dc.contributor.author | Risacher, Shannon L. | |
dc.contributor.author | Yoder, Karmen K. | |
dc.contributor.author | West, John D. | |
dc.contributor.author | Shen, Li | |
dc.contributor.author | Kim, Sungeun | |
dc.contributor.author | Inlow, Mark | |
dc.contributor.author | Foroud, Tatiana | |
dc.contributor.author | Jagust, William J. | |
dc.contributor.author | Koeppe, Robert A. | |
dc.contributor.author | Mathis, Chester A. | |
dc.contributor.author | Shaw, Leslie M. | |
dc.contributor.author | Trojanowski, John Q. | |
dc.contributor.author | Soares, Holly | |
dc.contributor.author | Aisen, Paul S. | |
dc.contributor.author | Petersen, Ronald C. | |
dc.contributor.author | Weiner, Michael W. | |
dc.contributor.author | Saykin, Andrew J. | |
dc.date.accessioned | 2020-01-13T15:03:37Z | |
dc.date.available | 2020-01-13T15:03:37Z | |
dc.date.issued | 2014-01 | |
dc.identifier.citation | Swaminathan, Shanker; Risacher, Shannon L.; Yoder, Karmen K.; West, John D.; Shen, Li; Kim, Sungeun; Inlow, Mark; Foroud, Tatiana; Jagust, William J.; Koeppe, Robert A.; Mathis, Chester A.; Shaw, Leslie M.; Trojanowski, John Q.; Soares, Holly; Aisen, Paul S.; Petersen, Ronald C.; Weiner, Michael W.; Saykin, Andrew J. (2014). "Association of plasma and cortical amyloid beta is modulated by APOE ε4 status." Alzheimer’s & Dementia 10(1): e9-e18. | |
dc.identifier.issn | 1552-5260 | |
dc.identifier.issn | 1552-5279 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/152522 | |
dc.description.abstract | BackgroundApolipoprotein E (APOE) ε4 allele’s role as a modulator of the relationship between soluble plasma amyloid beta (Aβ) and fibrillar brain Aβ measured by Pittsburgh compound B positron emission tomography ([11C]PiB PET) has not been assessed.MethodsNinety‐six Alzheimer’s Disease Neuroimaging Initiative participants with [11C]PiB scans and plasma Aβ1–40 and Aβ1–42 measurements at the time of PET scanning were included. Regional and voxelwise analyses of [11C]PiB data were used to determine the influence of APOE ε4 allele on association of plasma Aβ1–40, Aβ1–42, and Aβ1–40/Aβ1–42 with [11C]PiB uptake.ResultsIn APOE ε4− but not ε4+ participants, positive relationships between plasma Aβ1–40/Aβ1–42 and [11C]PiB uptake were observed. Modeling the interaction of APOE and plasma Aβ1–40/Aβ1–42 improved the explained variance in [11C]PiB binding compared with using APOE and plasma Aβ1–40/Aβ1–42 as separate terms.ConclusionsThe results suggest that plasma Aβ is a potential Alzheimer’s disease biomarker and highlight the importance of genetic variation in interpretation of plasma Aβ levels. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | ALZHEIMER’S & DEMENTIA | |
dc.subject.other | Pittsburgh compound B | |
dc.subject.other | Alzheimer’s disease | |
dc.subject.other | Mild cognitive impairment | |
dc.subject.other | Alzheimer’s Disease Neuroimaging Initiative | |
dc.subject.other | Amyloid beta | |
dc.subject.other | Plasma amyloid beta | |
dc.subject.other | Positron emission tomography | |
dc.subject.other | Apolipoprotein E | |
dc.title | Association of plasma and cortical amyloid beta is modulated by APOE ε4 status | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Neurology and Neurosciences | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/152522/1/alzjjalz201301007.pdf | |
dc.identifier.doi | 10.1016/j.jalz.2013.01.007 | |
dc.identifier.source | Alzheimer’s & Dementia | |
dc.identifier.citedreference | W.J. Jagust, S.M. Landau, L.M. Shaw, J.Q. Trojanowski, R.A. Koeppe, E.M. Reiman, et al. Relationships between biomarkers in aging and dementia. Neurology. 73: 2009; 1193 – 1199 | |
dc.identifier.citedreference | G.D. Rabinovici, W.J. Jagust. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 21: 2009; 117 – 128 | |
dc.identifier.citedreference | S.R. Choi, J.A. Schneider, D.A. Bennett, T.G. Beach, B.J. Bedell, S.P. Zehntner, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 26: 2012; 8 – 16 | |
dc.identifier.citedreference | C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, M.A. Mintun, et al. Use of florbetapir‐PET for imaging beta‐amyloid pathology. JAMA. 305: 2011; 275 – 283 | |
dc.identifier.citedreference | C.R. Jack Jr., V.J. Lowe, M.L. Senjem, S.D. Weigand, B.J. Kemp, M.M. Shiung, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 131: 2008; 665 – 680 | |
dc.identifier.citedreference | W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D.P. Holt, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound‐B. Ann Neurol. 55: 2004; 306 – 319 | |
dc.identifier.citedreference | D.F. Wong, P.B. Rosenberg, Y. Zhou, A. Kumar, V. Raymont, H.T. Ravert, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F‐AV‐45 (florbetapir [corrected] F 18). J Nucl Med. 51: 2010; 913 – 920 | |
dc.identifier.citedreference | R. Mayeux, N. Schupf. Blood‐based biomarkers for Alzheimer’s disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging. 32: 2011; S10 – S19 | |
dc.identifier.citedreference | F. Song, A. Poljak, M. Valenzuela, R. Mayeux, G.A. Smythe, P.S. Sachdev. Meta‐analysis of plasma amyloid‐beta levels in Alzheimer’s disease. J Alzheimers Dis. 26: 2011; 365 – 375 | |
dc.identifier.citedreference | A. Koyama, O.I. Okereke, T. Yang, D. Blacker, D.J. Selkoe, F. Grodstein. Plasma amyloid‐beta as a predictor of dementia and cognitive decline: a systematic review and meta‐analysis. Arch Neurol. 69: 2012; 824 – 831 | |
dc.identifier.citedreference | M. Thambisetty, S. Lovestone. Blood‐based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark Med. 4: 2010; 65 – 79 | |
dc.identifier.citedreference | E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 261: 1993; 921 – 923 | |
dc.identifier.citedreference | A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George‐Hyslop, M.A. Pericak‐Vance, S.H. Joo, et al. Association of apolipoprotein E allele epsilon 4 with late‐onset familial and sporadic Alzheimer’s disease. Neurology. 43: 1993; 1467 – 1472 | |
dc.identifier.citedreference | L.A. Farrer, L.A. Cupples, J.L. Haines, B. Hyman, W.A. Kukull, R. Mayeux, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta‐analysis: APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 278: 1997; 1349 – 1356 | |
dc.identifier.citedreference | E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, W. Lee, et al. Fibrillar amyloid‐beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A. 106: 2009; 6820 – 6825 | |
dc.identifier.citedreference | J.B. Toledo, H. Vanderstichele, M. Figurski, P.S. Aisen, R.C. Petersen, M.W. Weiner, et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 122: 2011; 401 – 413 | |
dc.identifier.citedreference | J.E. Donahue, C.E. Johanson. Apolipoprotein E, amyloid‐beta, and blood–brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 67: 2008; 261 – 270 | |
dc.identifier.citedreference | J.M. Castellano, J. Kim, F.R. Stewart, H. Jiang, R.B. DeMattos, B.W. Patterson, et al. Human apoE isoforms differentially regulate brain amyloid‐beta peptide clearance. Sci Transl Med. 3: 2011, 89ra57 | |
dc.identifier.citedreference | M.J. Sharman, M. Morici, E. Hone, T. Berger, K. Taddei, I.J. Martins, et al. APOE genotype results in differential effects on the peripheral clearance of amyloid‐beta42 in APOE knock‐in and knock‐out mice. J Alzheimers Dis. 21: 2010; 403 – 409 | |
dc.identifier.citedreference | K. Nishitsuji, T. Hosono, T. Nakamura, G. Bu, M. Michikawa. Apolipoprotein E regulates the integrity of tight junctions in an isoform‐dependent manner in an in vitro blood–brain barrier model. J Biol Chem. 286: 2011; 17536 – 17542 | |
dc.identifier.citedreference | A.M. Fagan, M.A. Mintun, R.H. Mach, S.Y. Lee, C.S. Dence, A.R. Shah, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 59: 2006; 512 – 519 | |
dc.identifier.citedreference | J.K. Lui, S.M. Laws, Q.X. Li, V.L. Villemagne, D. Ames, B. Brown, et al. Plasma amyloid‐beta as a biomarker in Alzheimer’s disease: the AIBL study of aging. J Alzheimers Dis. 20: 2010; 1233 – 1242 | |
dc.identifier.citedreference | D.P. Devanand, N. Schupf, Y. Stern, R. Parsey, G.H. Pelton, P. Mehta, et al. Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment. Neurology. 77: 2011; 125 – 131 | |
dc.identifier.citedreference | M.W. Weiner, P.S. Aisen, C.R. Jack Jr., W.J. Jagust, J.Q. Trojanowski, L. Shaw, et al. The Alzheimer’s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 6: 2010; 202 – 211 | |
dc.identifier.citedreference | W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, C.A. Mathis, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 6: 2010; 221 – 229 | |
dc.identifier.citedreference | K.J. Friston, A.P. Holmes, K.J. Worsley, J.P. Poline, C.D. Frith, R.S.J. Frackowiak. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 2: 1994; 189 – 210 | |
dc.identifier.citedreference | S. Swaminathan, L. Shen, S.L. Risacher, K.K. Yoder, J.D. West, S. Kim, et al. Amyloid pathway‐based candidate gene analysis of [(11)C]PiB‐PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav. 6: 2012; 1 – 15 | |
dc.identifier.citedreference | C.R. Jack Jr., M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, D. Harvey, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 27: 2008; 685 – 691 | |
dc.identifier.citedreference | S.L. Risacher, A.J. Saykin, J.D. West, L. Shen, H.A. Firpi, B.C. McDonald, et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res. 6: 2009; 347 – 361 | |
dc.identifier.citedreference | M.J. Figurski, T. Waligorska, J. Toledo, H. Vanderstichele, M. Korecka, V.M. Lee, et al. Improved protocol for measurement of plasma beta‐amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients. Alzheimers Dement. 8: 2012; 250 – 260 | |
dc.identifier.citedreference | A.J. Saykin, L. Shen, T.M. Foroud, S.G. Potkin, S. Swaminathan, S. Kim, et al. Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 6: 2010; 265 – 273 | |
dc.identifier.citedreference | R Core Team. R: a language and environment for statistical computing. 2012; R Foundation for Statistical Computing: Vienna, Austria | |
dc.identifier.citedreference | J.L. Lancaster, L.H. Rainey, J.L. Summerlin, C.S. Freitas, P.T. Fox, A.C. Evans, et al. Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward‐transform method. Hum Brain Mapp. 5: 1997; 238 – 242 | |
dc.identifier.citedreference | J.L. Lancaster, M.G. Woldorff, L.M. Parsons, M. Liotti, C.S. Freitas, L. Rainey, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 10: 2000; 120 – 131 | |
dc.identifier.citedreference | W.J. Strittmatter, A.M. Saunders, D. Schmechel, M. Pericak‐Vance, J. Enghild, G.S. Salvesen, et al. Apolipoprotein E: high‐avidity binding to beta‐amyloid and increased frequency of type 4 allele in late‐onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 90: 1993; 1977 – 1981 | |
dc.identifier.citedreference | W.J. Strittmatter, K.H. Weisgraber, D.Y. Huang, L.M. Dong, G.S. Salvesen, M. Pericak‐Vance, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform‐specific effects and implications for late‐onset Alzheimer disease. Proc Natl Acad Sci U S A. 90: 1993; 8098 – 8102 | |
dc.identifier.citedreference | D.E. Schmechel, A.M. Saunders, W.J. Strittmatter, B.J. Crain, C.M. Hulette, S.H. Joo, et al. Increased amyloid beta‐peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late‐onset Alzheimer disease. Proc Natl Acad Sci U S A. 90: 1993; 9649 – 9653 | |
dc.identifier.citedreference | C. Bachmeier, D. Paris, D. Beaulieu‐Abdelahad, B. Mouzon, M. Mullan, F. Crawford. A multifaceted role for apoE in the clearance of beta‐amyloid across the blood–brain barrier. Neurodegener Dis. 11: 2013; 13 – 21 | |
dc.identifier.citedreference | C. Bachmeier, D. Beaulieu‐Abdelahad, F. Crawford, M. Mullan, D. Paris. Stimulation of the retinoid X receptor facilitates beta‐amyloid clearance across the blood–brain barrier. J Mol Neurosci. 49: 2013; 270 – 276 | |
dc.identifier.citedreference | P.B. Jones, K.W. Adams, A. Rozkalne, T.L. Spires‐Jones, T.T. Hshieh, T. Hashimoto, et al. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid‐beta in human Alzheimer brain. PLoS One. 6: 2011; e14586 | |
dc.identifier.citedreference | N. Bien‐Ly, Y. Andrews‐Zwilling, Q. Xu, A. Bernardo, C. Wang, Y. Huang. C‐terminal‐truncated apolipoprotein (apo) E4 inefficiently clears amyloid‐beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice. Proc Natl Acad Sci U S A. 108: 2011; 4236 – 4241 | |
dc.identifier.citedreference | Alzheimer’s Association. 2012 Alzheimer’s disease facts and figures. Alzheimers Dement. 8: 2012; 131 – 168 | |
dc.identifier.citedreference | H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, J. Hardy, et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 9: 2010; 560 – 574 | |
dc.identifier.citedreference | R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, E. Kokmen. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 56: 1999; 303 – 308 | |
dc.identifier.citedreference | M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7: 2011; 270 – 279 | |
dc.identifier.citedreference | L.M. Shaw, H. Vanderstichele, M. Knapik‐Czajka, C.M. Clark, P.S. Aisen, R.C. Petersen, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s Disease Neuroimaging Initiative subjects. Ann Neurol. 65: 2009; 403 – 413 | |
dc.identifier.citedreference | O.C. Okonkwo, M.M. Mielke, H.R. Griffith, A.R. Moghekar, R.J. O’Brien, L.M. Shaw, et al. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol. 68: 2011; 113 – 119 | |
dc.identifier.citedreference | P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, O. Hansson. Cerebrospinal fluid levels of beta‐amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 69: 2012; 98 – 106 | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.